Effects of Bilio-Pancreatic Diversion on Diabetic Complications A 10-year follow-up

被引:118
作者
Iaconelli, Amerigo [1 ]
Panunzi, Simona [2 ]
De Gaetano, Andrea [2 ]
Manco, Melania [3 ,4 ]
Guidone, Caterina [1 ]
Leccesi, Laura [1 ]
Gniuli, Donatella [1 ]
Nanni, Giuseppe [5 ]
Castagneto, Marco [5 ]
Ghirlanda, Giovanni [1 ]
Mingrone, Geltrude [1 ]
机构
[1] Catholic Univ, Dept Internal Med, Rome, Italy
[2] CNR Inst Syst Anal & Comp Sci, BioMathLab, Rome, Italy
[3] Bambino Gesu Pediat Hosp, Rome, Italy
[4] Ist Ricovero & Cura Carattere Sci, Res Inst, Rome, Italy
[5] Catholic Univ, Dept Surg, Rome, Italy
关键词
BARIATRIC SURGERY; GLUCOSE CONTROL; CARDIOVASCULAR RISK; TYPE-2; PREVENTION; MELLITUS; OBESITY;
D O I
10.2337/dc10-1761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-The surgical option could represent a valid alternative to medical therapy in some diabetic patients. However, no data are available on long-term effects of metabolic surgery on diabetic complications. We aimed to determine whether patients with newly diagnosed type 2 diabetes who underwent bilio-pancreatic diversion (BPD) had less micro- and macrovascular complications than those who received conventional therapy. RESEARCH DESIGN AND METHODS-This was an unblinded, case-controlled trial with 10-years' follow-up, conducted from July 1998 through October 2009 at the Day Hospital of Metabolic Diseases, Catholic University, Rome, Italy. A consecutive sample of 110 obese patients (BMI > 35 kg/m(2)) with newly diagnosed type 2 diabetes was enrolled. The study was completed by 50 subjects. The main outcome measure was long-term effects (10 years) of BPD versus those associated with conventional therapy on microvascular outcome, micro- and macroalbuminuria, and glomerular filtration rate (GFR). Secondary measures included macrovascular outcomes, type 2 diabetes remission, glycated hemoglobin, and hyperlipidemia. RESULTS-Ten-year GFR variation was -45.7 +/- 18.8% in the medical arm and 13.6 +/- 24.5% in the surgical arm (P < 0.001). Ten-year hypercreatininemia prevalence was 39.3% in control subjects and 9% in BPD subjects (P = 0.001). After 10 years, all BPD subjects recovered from microalbuminuria, whereas microalbuminuria appeared or progressed to macroalbuminuria in control subjects. Three myocardial infarctions, determined by electrocardiogram, and one stroke occurred in control subjects. After the 10-year follow-up, coronary heart disease (CHD) probability was 0.22 +/- 0.10 and 0.05 +/- 0.04 in the medical and surgical groups, respectively (P < 0.001). Remission from type 2 diabetes was observed in all patients within 1 year of surgery. Surgical and medical subjects had lost 34.60 +/- 10.25 and 0.38 +/- 6.10% of initial weight at the 10-year follow-up (P < 0.001). CONCLUSIONS-Renal and cardiovascular complications were dramatically reduced in the surgical arm, indicating long-term benefits of BPD on diabetic complications, at least in the case of morbid obesity with decompensated type 2 diabetes.
引用
收藏
页码:561 / 567
页数:7
相关论文
共 24 条
[1]   Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion [J].
Balsa, J. A. ;
Botella-Carretero, J. I. ;
Peromingo, R. ;
Zamarron, I. ;
Arrieta, F. ;
Munoz-Malo, T. ;
Vazquez, C. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (10) :845-850
[2]   Bariatric surgery: A systematic review and meta-analysis [J].
Buchwald, H ;
Avidor, Y ;
Braunwald, E ;
Jensen, MD ;
Pories, W ;
Fahrbach, K ;
Schoelles, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (14) :1724-1737
[3]   Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis [J].
Buchwald, Henry ;
Estok, Rhonda ;
Fahrbach, Kyle ;
Banel, Deirdre ;
Jensen, Michael D. ;
Pories, Walter J. ;
Bantle, John P. ;
Sledge, Isabella .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (03) :248-U81
[4]   How Do We Define Cure of Diabetes? [J].
Buse, John B. ;
Caprio, Sonia ;
Cefalu, William T. ;
Ceriello, Antonio ;
Del Prato, Stefano ;
Inzucchi, Silvio E. ;
McLaughlin, Sue ;
Phillips, Gordon L., II ;
Robertson, R. Paul ;
Rubino, Francesco ;
Kahn, Richard ;
Kirkman, M. Sue .
DIABETES CARE, 2009, 32 (11) :2133-2135
[5]   Clinical Results and Nutritional Consequences of Biliopancreatic Diversion: Three Years of Follow-Up [J].
de Luis, D. A. ;
Pacheco, D. ;
Izaola, O. ;
Terroba, M. C. ;
Cuellar, L. ;
Martin, T. .
ANNALS OF NUTRITION AND METABOLISM, 2008, 53 (3-4) :234-239
[6]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[7]   Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes [J].
Duckworth, William ;
Abraira, Carlos ;
Moritz, Thomas ;
Reda, Domenic ;
Emanuele, Nicholas ;
Reaven, Peter D. ;
Zieve, Franklin J. ;
Marks, Jennifer ;
Davis, Stephen N. ;
Hayward, Rodney ;
Warren, Stuart R. ;
Goldman, Steven ;
McCarren, Madeline ;
Vitek, Mary Ellen ;
Henderson, William G. ;
Huang, Grant D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) :129-U62
[8]   Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial [J].
Garber, Alan ;
Henry, Robert ;
Ratner, Robert ;
Garcia-Hernandez, Pedro A. ;
Rodriguez-Pattzi, Hiromi ;
Olvera-Alvarez, Israel ;
Hale, Paula M. ;
Zdravkovic, Milan ;
Bode, Bruce .
LANCET, 2009, 373 (9662) :473-481
[9]  
Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
[10]   Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: Current knowledge and rationale for the action to control cardiovascular risk in diabetes (ACCORD) trial [J].
Goff, David C., Jr. ;
Gerstein, Hertzel C. ;
Ginsberg, Henry N. ;
Cushman, William C. ;
Margolis, Karen L. ;
Byington, Robert P. ;
Buse, John B. ;
Genuth, Saul ;
Probstfield, Jeffrey L. ;
Simons-Morton, Denise G. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12A) :4I-20I